- Home
- NFJ vs NUVB Comparison
NFJ vs NUVB Comparison
Compare NFJ & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NFJ | NUVB |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.7B |
| IPO Year | 2003 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NFJ | NUVB |
|---|---|---|
| Price | $14.23 | $4.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 332.8K | ★ 5.1M |
| Earning Date | 01-01-0001 | 11-04-2026 |
| Dividend Yield | ★ 9.01% | N/A |
| EPS Growth | N/A | ★ 71.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $62,902,000.00 |
| Revenue This Year | N/A | $209.36 |
| Revenue Next Year | N/A | $41.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 698.96 |
| 52 Week Low | $12.25 | $4.05 |
| 52 Week High | $15.75 | $9.75 |
Technical Indicators
Market Signals| Indicator | NFJ | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 33.31 | 41.73 |
| Support Level | $14.14 | $4.38 |
| Resistance Level | $15.20 | $5.11 |
| Average True Range (ATR) | 0.20 | 0.23 |
| MACD | -0.03 | 0.06 |
| Stochastic Oscillator | 10.46 | 54.47 |
Price Performance
Historical ComparisonAbout NFJ Virtus Dividend Interest & Premium Strategy Fund of Beneficial Interest
Virtus Dividend, Interest & Premium Strategy Fund is a Massachusetts-based business trust. The primary investment objective of the company is to seek current income and gains, with a secondary objective of long-term capital appreciation. It pursues its investment objectives by investing in a diversified portfolio of dividend-paying common stocks and income-producing convertible securities.
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.